41.000 makale bulundu

Freezing of Gait: A Therapeutic Perspective.

LeWitt PA.

Eur J Neurosci · 2026-10-01

DOI: 10.1111/ejn.70711PMID: 42865107

Beyond Single-Target Therapy: Dual-Acting Cannabinoid Type-2 Receptor Modulation in Neurological Disorders.

Bindra S, Rangarajan TM, Parambi DGT, Kumar S, Anal JMH, Mathew B.

ChemMedChem · 2026-10-01

DOI: 10.1002/cmdc.70521PMID: 42870385

Ergothioneine Mediated Neuroprotective Effects in the Nervous System.

Saha T, Frisina RD, Zhu X, Park C, Ding B, Walton JP, Bazard P.

Mol Nutr Food Res · 2026-10-01

DOI: 10.1002/mnfr.70619PMID: 42876395

Therapeutic and Biomedical Applications of Dopamine-Derived Scaffolds: A Comprehensive Review.

Kaboudin B, Barati A.

ChemMedChem · 2026-10-01

DOI: 10.1002/cmdc.70547PMID: 42897744

Effect of Different Cortical Targets of Transcranial Magnetic Stimulation on Freezing of Gait in Parkinsonism: A Systematic Review.

Adel M, Zayed R, Mohamed A, Abdelnaby N, Hatim N, Abdelhamed Y, Abdelwahab E, Araby N, Hany M, Abdelhaleem D, Elabd A.

Physiother Res Int · 2026-10-01

DOI: 10.1002/pri.70360PMID: 42899368

Modulating Microglial Activation Through GLP-1 Pathways: A New Frontier in Neuroinflammation Research.

Lakshmi SM, Singh V, Vanangamudi M, Taj T, Shahin Dh H, Nath R, Dutta G, Avvari SK, Sridhar SB, Panigrahy UP, Noushida N, Chaudhary P.

Eur J Neurosci · 2026-10-01

DOI: 10.1111/ejn.70718PMID: 42904474

Gut-Derived α-Synuclein Condensates in Parkinson's Disease: Linking Liquid-Liquid Phase Separation, Blood Dissemination, and Chemical Biology.

Arichandran J, Hsiao SH, Lee CI.

ChemMedChem · 2026-10-01

DOI: 10.1002/cmdc.70545PMID: 42922065

Alzheimer ve Parkinson hastalıklarında bağırsak-beyin ekseni: karşılaştırmalı bir bakış açısı.

The gut-brain axis in Alzheimer's and Parkinson's diseases: a comparative perspective.

Upadhyay R, C C, Kar S, Sathyamoorthy S, Pitchaimuthu X, Sevanan M.

Front Microbiomes · 2026-09-30

DOI: 10.3389/frmbi.2026.1942228PMID: 42877500

NAD<sup>+</sup> Parkinson hastalığında sinyalizasyon: moleküler mekanizmalar ve terapötik bakış açıları.

NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.

Wang T, Zhou X, Chen X.

Front Neurol · 2026-09-30

DOI: 10.3389/fneur.2026.1943801PMID: 42877680

Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson's Disease: Evidence Review and Expert Opinion.

Shah A, Dodel R, Kharawala S, Klapper K, May M, Odin P, Asis A, Pagano G, Kotzeva A, Carroll C.

Pharmacoeconomics · 2026-09-30

DOI: 10.1007/s40273-026-01669-2PMID: 42814382

The eyes and Parkinsonian syndromes.

Chen BS, Sandlin DS, Biousse V.

Rev Neurol (Paris) · 2026-09-30

DOI: 10.1016/j.neurol.2026.09.005PMID: 42816189

GLP-1, GIP ve Glucagon Reseptör Agonizmi Obezite-Neurodejenerasyon Arabirimi: Anlatısal Bir İnceleme.

GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.

Popa E, Popa AE, Poroch V, Schreiner TG, Slanina AM, Poroch M, Hatneanu AM, Ungureanu MI, Petroaie AD, Bacusca AI, Coman EA.

Int J Mol Sci · 2026-09-30

DOI: 10.3390/ijms27198738PMID: 42883986